| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
36,286 |
31,575 |
$3.07M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
25,962 |
21,817 |
$3.05M |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
5,990 |
5,460 |
$632K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
1,564 |
1,379 |
$520K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
5,298 |
4,500 |
$508K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
4,790 |
4,430 |
$505K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
3,697 |
3,256 |
$484K |
| 92587 |
|
16,111 |
14,609 |
$357K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
3,016 |
2,664 |
$338K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
2,075 |
1,979 |
$286K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
6,421 |
5,750 |
$189K |
| 90670 |
|
2,062 |
1,909 |
$165K |
| 90686 |
|
4,787 |
4,347 |
$96K |
| D1206 |
Topical application of fluoride varnish |
2,744 |
2,698 |
$68K |
| 95930 |
|
801 |
721 |
$57K |
| 87486 |
|
1,567 |
1,379 |
$44K |
| 87581 |
|
1,564 |
1,379 |
$44K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
1,563 |
1,379 |
$43K |
| 92567 |
|
2,442 |
2,108 |
$39K |
| 90677 |
|
388 |
303 |
$35K |
| 99215 |
Prolong outpt/office vis |
182 |
127 |
$29K |
| 96127 |
|
5,212 |
4,505 |
$23K |
| 90723 |
|
1,095 |
963 |
$22K |
| 90647 |
|
996 |
910 |
$21K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
1,783 |
1,657 |
$20K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
299 |
251 |
$16K |
| 96160 |
|
5,665 |
4,848 |
$14K |
| 99177 |
|
2,945 |
2,786 |
$14K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
686 |
642 |
$14K |
| 87631 |
|
112 |
108 |
$13K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
362 |
330 |
$11K |
| 90656 |
|
382 |
345 |
$8K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
93 |
91 |
$7K |
| 81002 |
|
2,435 |
2,179 |
$7K |
| 90633 |
|
327 |
291 |
$7K |
| 90734 |
|
216 |
166 |
$4K |
| 0002A |
|
104 |
104 |
$4K |
| 90681 |
|
190 |
179 |
$4K |
| 90651 |
|
183 |
138 |
$4K |
| 83655 |
|
321 |
294 |
$3K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
252 |
197 |
$3K |
| 90661 |
|
108 |
98 |
$3K |
| 81025 |
|
383 |
336 |
$3K |
| 0001A |
|
63 |
61 |
$2K |
| A4558 |
Conductive gel or paste, for use with electrical device (e.g., tens, nmes), per oz |
819 |
721 |
$2K |
| 83718 |
|
301 |
251 |
$2K |
| 85018 |
|
831 |
684 |
$2K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
34 |
32 |
$1K |
| 36415 |
Collection of venous blood by venipuncture |
600 |
517 |
$1K |
| 0072A |
|
31 |
31 |
$1K |
| 87807 |
|
99 |
87 |
$1K |
| 0071A |
|
31 |
27 |
$1K |
| 82465 |
|
304 |
251 |
$1K |
| 90620 |
|
48 |
41 |
$933.57 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
71 |
67 |
$926.12 |
| A4556 |
Electrodes, (e.g., apnea monitor), per pair |
778 |
679 |
$725.40 |
| 90715 |
|
19 |
14 |
$419.04 |
| A7004 |
Small volume nonfiltered pneumatic nebulizer, disposable |
253 |
198 |
$125.55 |
| 81003 |
|
50 |
40 |
$104.06 |
| 94760 |
|
75 |
60 |
$73.59 |
| 94664 |
|
14 |
14 |
$68.81 |
| 99051 |
|
37 |
36 |
$51.33 |
| 97802 |
|
20 |
13 |
$25.00 |
| A6411 |
Eye pad, non-sterile, each |
826 |
721 |
$16.39 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
249 |
195 |
$9.85 |
| 99072 |
|
379 |
363 |
$0.00 |
| G8431 |
Screening for depression is documented as being positive and a follow-up plan is documented |
18 |
13 |
$0.00 |
| 3008F |
|
3,922 |
3,243 |
$0.00 |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
1,503 |
1,140 |
$0.00 |
| 99000 |
|
98 |
83 |
$0.00 |
| 99070 |
|
13 |
13 |
$0.00 |